Market Newsdesk

SHENZHEN, China, Aug. 31, 2026 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended June 30, 2026.

Mr. Jay Wenjie Xiao, Chairman and Chief Executive Officer of Lexin, commented, “During the second quarter, the industry environment remained complex. Nevertheless, by prioritizing regulatory compliance and leveraging our diversified business ecosystem, we maintained our operational resilience. For the quarter, our GMV reached 55.4 billion, with total revenue of 3.2 billion and net income of 101 million.

In late June, risk events involving certain industry peers led to a sector-wide tightening of funding supply, impacting broader market sentiment and loan volume. In response, we have taken a disciplined approach to fortify our position: carefully managing our cost structure to enhance operational resilience, refining our risk parameters to safeguard asset quality, optimizing liquidity management for capital efficiency, and advancing our business diversification.

While near-term market uncertainty may persist for some time, our diversified business ecosystem provides a foundation for long-term sustainable operations and tech-empowerment transformation. We remain confident in the long-term fundamentals of our business.

Looking ahead, given the ongoing industry uncertainties, the Board has made a prudent decision to adjust our dividend policy to an annual evaluation cycle to preserve liquidity and maintain a financial buffer to support our business transformation. When market conditions stabilize and our operational performance recovers, the Board will actively evaluate options, including potential share repurchases, to enhance shareholder returns,” Mr. Xiao concluded.

Mr. James Zheng, Chief Financial Officer of Lexin, commented, “During the second quarter, we continued to advance our business transformation under the new regulatory framework that took effect in the fourth quarter of last year, achieving progress that largely met our expectations.

The recent risk events involving certain industry players have sector-wide effects, and we have been correspondingly impacted by these headwinds. While we are taking proactive measures to mitigate these uncertainties, our near-term performance will foreseeably remain under considerable pressure. As we manage through this industry transition, we remain highly disciplined, scaling back volume to prioritize asset quality. Our immediate focus is to safeguard our liquidity, fortify our balance sheet, and position the Company to resume sustainable growth once market conditions normalize.”

Second Quarter Operational Highlights:

User Base

• Total number of registered users across our platform reached 253 million as of June 30, 2026, representing an increase of 7.2% from 236 million as of June 30, 2025.
• Number of active users¹ in the second quarter of 2026 was 5.0 million, representing an increase of 6.1% from 4.7 million in the second quarter of 2025.
• Number of cumulative borrowers with successful drawdown was 39.2 million as of June 30, 2026, an increase of 11.4% from 35.2 million as of June 30, 2025.

Loan Facilitation Business

• As of June 30, 2026, we cumulatively originated RMB1,644 billion in loans, an increase of 15.0% from RMB1,430 billion as of June 30, 2025.

• Total loan originations² in the second quarter of 2026 was RMB55.4 billion, an increase of 4.8% from RMB52.9 billion in the second quarter of 2025.
• Total outstanding principal balance of loans³ was RMB93.7 billion as of June 30, 2026, representing a decrease of 11.4% from RMB106 billion as of June 30, 2025.

Credit Performance

⁴

• 90 day+ delinquency ratio⁵ was 3.6% as of June 30, 2026, as compared with 3.5% as of March 31, 2026.
• First payment default rate (30 day+) for new loan originations was below 1% as of June 30, 2026.

Installment E-commerce Platform Service

• GMV⁶ in the second quarter of 2026 for our installment e-commerce platform service was RMB2,342 million, representing an increase of 15.5% from RMB2,029 million in the second quarter of 2025.
• In the second quarter of 2026, our installment e-commerce platform service served over 700,000 users.

Other Operational Highlights

• The weighted average tenor of loans originated in the second quarter of 2026 was approximately 10.7 months, as compared with 13.2 months in the second quarter of 2025.
• Repeated borrowers’ contribution⁷ of loans across our platform for the second quarter of 2026 was 85.7%.

Second Quarter 2026 Financial Highlights:

• Total operating revenue was RMB3,187 million, representing a decrease of 11.2% from the second quarter of 2025.
• Credit facilitation service income was RMB1,930 million, representing a decrease of 15.0% from the second quarter of 2025. Tech-empowerment service income was RMB473 million, representing a decrease of 43.0% from the second quarter of 2025. Installment e-commerce platform service income was RMB784 million, representing an increase of 60.8% from the second quarter of 2025.
• Net income attributable to ordinary shareholders of the Company was RMB101 million, representing a decrease of 80.2% from the second quarter of 2025. Net income per ADS attributable to ordinary shareholders of the Company was RMB0.61 on a fully diluted basis.
• Adjusted net income attributable to ordinary shareholders of the Company⁸ was RMB127 million, representing a decrease of 76.4% from the second quarter of 2025. Adjusted net income per ADS attributable to ordinary shareholders of the Company⁸ was RMB0.76 on a fully diluted basis.

__________________________

1. Active users refer to, for a specified period, users who made at least one transaction during that period through our platform or through our third-party partners’ platforms using the credit line granted by us.
2. Total loan originations refer to the total principal amount of loans originated during the given period through our platform or through our third-party partners’ platforms.
3. Total outstanding principal balance of loans refers to the total amount of principal outstanding for loans facilitated and originated at the end of each period, including loans guaranteed by our financial guarantee companies and the loans facilitated across third party platforms that we bear principal risk and excluding loans delinquent for more than 180 days that are charged-off.
4. Loans under Intelligent Credit Platform are excluded from the calculation of credit performance. Intelligent Credit Platform (ICP) is an intelligent platform on our “Fenqile” app, under which we match borrowers and financial institutions through big data and cloud computing technology. For loans facilitated through ICP, the Company does not bear principal risk.
5. “90 day+ delinquency rate” refers to the outstanding principal balance of on- and off-balance sheet loans that were 91 to 180 calendar days past due as a percentage of the total outstanding principal balance of on- and off-balance sheet loans across our platform and those loans across third party platforms that we bear principle risk as of a specific date. Loans that are charged-off and loans under “ICP”, E-commerce business and overseas are not included in the delinquency rate calculation.
6. GMV refers to the total value of transactions completed for products purchased on our e-commerce and Maiya channel, net of returns.
7. Repeated borrowers’ contribution for a given period refers to the principal amount of loans borrowed during that period by borrowers who had previously made at least one successful drawdown as a percentage of the total loan facilitation and origination volume through our platform during that period.
8. Adjusted net income attributable to ordinary shareholders of the Company, adjusted net income per ordinary share and per ADS attributable to ordinary shareholders of the Company are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section of “Use of Non-GAAP Financial Measures Statement” and the tables captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Second Quarter 2026 Financial Results:

Operating revenue was RMB3,187 million in the second quarter of 2026, as compared to RMB3,587 million in the second quarter of 2025.

Credit facilitation service income was RMB1,930 million in the second quarter of 2026, as compared to RMB2,270 million in the second quarter of 2025. The decrease was due to the decrease in loan facilitation and servicing fees-credit oriented revenue, as well as financing income.

Loan facilitation and servicing fees-credit oriented was RMB738 million in the second quarter of 2026, as compared to RMB1,131 million in the second quarter of 2025. The decrease was primarily due to the decrease in the APR of off-balance sheet loans and the decrease in origination of off-balance sheet loans.

Guarantee income was RMB759 million in the second quarter of 2026, as compared to RMB571 million in the second quarter of 2025. The increase was primarily due to the increase of outstanding balances in the off-balance sheet loans funded by certain institutional funding partners, which are accounted for under ASC 460, Guarantees.

Financing income was RMB433 million in the second quarter of 2026, as compared to RMB568 million in the second quarter of 2025.The decrease was primarily driven by the decrease in the outstanding balances of on-balance sheet loans.

Tech-empowerment service income was RMB473 million in the second quarter of 2026, as compared to RMB830 million in the second quarter of 2025. The decrease was primarily due to the decrease of loan facilitation volume through ICP.

Installment e-commerce platform service income was RMB784 million in the second quarter of 2026, as compared to RMB487 million in the second quarter of 2025. The increase was primarily driven by the increase in transaction volume.

Cost of sales consisted of cost of inventory sold and other costs. Cost of sales was RMB484 million in the second quarter of 2026, as compared to RMB426 million in the second quarter of 2025. The increase was primarily driven by the increase in transaction volume of online direct sales which is recorded on a gross basis.

Funding cost was RMB24.5 million in the second quarter of 2026, as compared to RMB59.9 million in the second quarter of 2025. The decrease was primarily driven by the decrease in funding rates and balance of funding debts to fund the on-balance sheet loans.

Processing and servicing costs was RMB546 million in the second quarter of 2026, as compared to RMB606 million in the second quarter of 2025.

Provision for financing receivables was RMB410 million in the second quarter of 2026, as compared to RMB257 million in the second quarter of 2025. The increase was primarily due to the decrease in performance of the on-balance sheet loans.

Provision for contract assets and receivables was RMB174 million in the second quarter of 2026, as compared to RMB164 million in the second quarter of 2025.

Provision for contingent guarantee liabilities was RMB1,052 million in the second quarter of 2026, as compared to RMB802 million in the second quarter of 2025. The increase was primarily due to the increase of outstanding balances in the off-balance sheet loans funded by certain institutional funding partners, which are accounted for under ASC 460, Guarantees.

Gross profit was RMB496 million in the second quarter of 2026, as compared to RMB1,273 million in the second quarter of 2025.

Sales and marketing expenses was RMB347 million in the second quarter of 2026, as compared to RMB567 million in the second quarter of 2025. The decrease was primarily driven by the decrease in advertising fees.

Research and development expenses was RMB147 million in the second quarter of 2026, as compared to RMB158 million in the second quarter of 2025.

General and administrative expenses was RMB107 million in the second quarter of 2026, as compared to RMB96.0 million in the second quarter of 2025.

Change in fair value of financial guarantee derivatives and loans at fair value was a gain of RMB238 million in the second quarter of 2026, as compared to a gain of RMB184 million in the second quarter of 2025. The change was primarily driven by the fair value gains realized as a result of the release of guarantee obligation as loans are repaid, partially offset by the fair value loss from the re-measurement of the expected loss rates.

Income tax expense was RMB53.5 million in the second quarter of 2026, as compared to RMB120 million in the second quarter of 2025. The decrease was primarily due to the decrease in income before income tax expense.

Net income was RMB101 million in the second quarter of 2026, as compared to RMB511 million in the second quarter of 2025.

Recent Development

Update of Share Repurchase Program

Pursuant to the Company’s share repurchase program of up to US$50 million adopted in July 2025, the Company repurchased a total of approximately 9.6 million ADSs (equivalent to 19.2 million Class A ordinary shares) for approximately US$39 million. The total number of shares repurchased by the Company since the adoption of the share repurchase program amounted to approximately 5.8% of its total ordinary shares outstanding as of June 30, 2026.

Updated Dividend Policy

On August 31, 2026, the Board approved an updated dividend policy, under which the Company will distribute 30% of total net income as cash dividends on an annual basis, effective from fiscal year 2026. This represents a change from the previous semi-annual distribution. Any potential dividend for fiscal year 2026 will be determined in conjunction with the announcement of the Company’s full-year results in early 2027.

Business Outlook

Looking ahead, given the ongoing industry and regulatory uncertainties, we anticipate total loan origination for the third quarter of 2026 to decrease significantly on a quarter-over-quarter basis and we may incur a net loss for the quarter.

This forecast reflects our current preliminary views, which are subject to the impact of macroeconomic factors. The Company may adjust its performance outlook as appropriate based on evolving circumstances.

Conference Call

The Company’s management will host an earnings conference call at 7:00 AM U.S. Eastern time on August 31, 2026 (7:00 PM Beijing/Hong Kong time on August 31, 2026).

Participants who wish to join the conference call should register online at:

https://register-conf.media-server.com/register/BI1de4908791bd49b8b7d1448ef38c027a

Once registration is completed, each participant will receive the dial-in number and a unique access PIN for the conference call.

Participants joining the conference call should dial in at least 10 minutes before the scheduled start time.

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.lexin.com.

About LexinFintech Holdings Ltd.

We are a leading credit technology-empowered personal financial service enabler. Our mission is to use technology and risk management expertise to make financing more accessible for young generation consumers. We strive to achieve this mission by connecting consumers with financial institutions, where we facilitate through a unique model that includes online and offline channels, installment consumption platform, big data and AI driven credit risk management capabilities, as well as smart user and loan management systems. We also empower financial institutions by providing cutting-edge proprietary technology solutions to meet their needs of financial digital transformation.

For more information, please visit http://ir.lexin.com.

To follow us on Twitter, please go to: https://twitter.com/LexinFintech.

Use of Non-GAAP Financial Measures Statement

In evaluating our business, we consider and use adjusted net income attributable to ordinary shareholders of the Company, non-GAAP EBIT, adjusted net income per ordinary share and per ADS attributable to ordinary shareholders of the Company, four non-GAAP measures, as supplemental measures to review and assess our operating performance. The presentation of the non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define adjusted net income attributable to ordinary shareholders of the Company as net income attributable to ordinary shareholders of the Company excluding share-based compensation expenses, interest expense associated with convertible notes, and investment income/(loss) and we define non-GAAP EBIT as net income excluding income tax expense, share-based compensation expenses, interest expense, net, and investment income/(loss).

We present these non-GAAP financial measures because they are used by our management to evaluate our operating performance and formulate business plans. Adjusted net income attributable to ordinary shareholders of the Company enables our management to assess our operating results without considering the impact of share-based compensation expenses, interest expense associated with convertible notes, and investment income/(loss). Non-GAAP EBIT, on the other hand, enables our management to assess our operating results without considering the impact of income tax expense, share-based compensation expenses, interest expense, net, and investment income/(loss). We also believe that the use of these non-GAAP financial measures facilitates investors’ assessment of our operating performance. These non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP.

These non-GAAP financial measures have limitations as an analytical tool. One of the key limitations of using adjusted net income attributable to ordinary shareholders of the Company and non-GAAP EBIT is that they do not reflect all items of income and expense that affect our operations. Share-based compensation expenses, interest expense associated with convertible notes, income tax expense, interest expense, net, and investment income/(loss) have been and may continue to be incurred in our business and are not reflected in the presentation of adjusted net income attributable to ordinary shareholders of the Company and non-GAAP EBIT. Further, these non-GAAP financial measures may differ from the non-GAAP financial information used by other companies, including peer companies, and therefore their comparability may be limited.

We compensate for these limitations by reconciling each of the non-GAAP financial measures to the most directly comparable U.S. GAAP financial measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

Exchange Rate Information Statement

This announcement contains translations of certain RMB amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB6.7851 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on June 30, 2026. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Lexin’s beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the expectation of the collection efficiency and delinquency, business outlook and quotations from management in this announcement, contain forward-looking statements. Lexin may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Lexin’s goal and strategies; Lexin’s expansion plans; Lexin’s future business development, financial condition and results of operations; Lexin’s expectation regarding demand for, and market acceptance of, its credit and investment management products; Lexin’s expectations regarding keeping and strengthening its relationship with borrowers, institutional funding partners, merchandise suppliers and other parties it collaborates with; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Lexin’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Lexin does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

LexinFintech Holdings Ltd. 
IR inquiries: 
Will Tan 
Tel: +86 (755) 3637-8888 ext. 6258 
E-mail: [email protected]

Media inquiries: 
Ruifeng Xu 
Tel: +86 (755) 3637-8888 ext. 6993 
E-mail: [email protected]

SOURCE LexinFintech Holdings Ltd.

LexinFintech Holdings Ltd. Unaudited Condensed Consolidated Balance Sheets
	As of
(In thousands)	December 31, 2025			June 30, 2026
	RMB			RMB			US$
ASSETS
Current Assets
Cash and cash equivalents		2,156,133			1,232,362			181,628
Restricted cash		1,717,773			1,164,978			171,697
Restricted term deposit and short-term investments		78,458			51,671			7,615
Short-term financing receivables, net(1)		5,450,418			4,749,246			699,952
Short-term contract assets and receivables, net(1)		3,763,096			3,699,274			545,206
Deposits to insurance companies and guarantee companies		2,187,609			2,234,221			329,283
Prepayments and other current assets		2,858,054			4,323,650			637,227
Amounts due from related parties		84,531			132,320			19,502
Inventories, net		24,119			26,321			3,879
Total Current Assets		18,320,191			17,614,043			2,595,989
Non-current Assets
Restricted cash		91,937			82,831			12,208
Long-term financing receivables, net(1)		167,378			108,331			15,966
Long-term contract assets and receivables, net(1)		317,496			215,181			31,714
Property, equipment and software, net		895,046			1,018,803			150,153
Land use rights, net		828,467			811,267			119,566
Long-term investments		243,971			243,960			35,955
Deferred tax assets		1,763,235			1,857,317			273,735
Other assets		535,242			430,349			63,426
Total Non-current Assets		4,842,772			4,768,039			702,723
TOTAL ASSETS		23,162,963			22,382,082			3,298,712
LIABILITIES
Current liabilities
Accounts payable		101,178			148,155			21,835
Amounts due to related parties		8,708			9,172			1,352
Short-term borrowings and current portion of long-term borrowings		905,791			839,501			123,727
Short-term funding debts		2,440,685			998,347			147,138
Deferred guarantee income		1,305,911			1,558,203			229,651
Contingent guarantee liabilities		544,191			571,066			84,165
Accruals and other current liabilities		4,371,484			4,314,904			635,938
Total Current Liabilities		9,677,948			8,439,348			1,243,806
Non-current Liabilities
Long-term borrowings		566,015			639,695			94,279
Long-term funding debts		850,590			1,209,872			178,313
Deferred tax liabilities		105,212			81,401			11,997
Other long-term liabilities		10,567			10,550			1,555
Total Non-current Liabilities		1,532,384			1,941,518			286,144
TOTAL LIABILITIES		11,210,332			10,380,866			1,529,950
Shareholders’ equity:
Class A Ordinary Shares		209			184			28
Class B Ordinary Shares		41			41			7
Treasury stock		(493,846	)		(269,850	)		(39,771	)
Additional paid-in capital		3,396,667			3,142,342			463,124
Statutory reserves		1,260,923			1,260,923			185,837
Accumulated other comprehensive income		(27,597	)		(27,342	)		(4,030	)
Retained earnings		7,816,234			7,894,918			1,163,567
Total shareholders’ equity		11,952,631			12,001,216			1,768,762
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		23,162,963			22,382,082			3,298,712

__________________________
(1)  Short-term financing receivables, net of allowance for credit losses of RMB198,694 and RMB264,769 as of December 31, 2025 and June 30, 2026, respectively.

Short-term contract assets and receivables, net of allowance for credit losses of RMB259,054 and RMB294,664 as of December 31, 2025 and June 30, 2026, respectively.

Long-term financing receivables, net of allowance for credit losses of RMB3,723 and RMB3,691 as of December 31, 2025 and June 30, 2026, respectively.

Long-term contract assets and receivables, net of allowance for credit losses of RMB14,569 and RMB4,598 as of December 31, 2025 and June 30, 2026, respectively.

LexinFintech Holdings Ltd. Unaudited Condensed Consolidated Statements of Operations
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
(In thousands, except for share and per share data)	2025			2026							2025			2026
	RMB			RMB			US$				RMB			RMB			US$
Operating revenue:
Credit facilitation service income		2,269,846			1,930,271			284,487				4,460,712			4,161,942			613,394
Loan facilitation and servicing fees-credit oriented		1,130,734			738,377			108,823				2,266,963			1,776,306			261,795
Guarantee income		571,181			758,525			111,793				1,118,995			1,485,601			218,950
Financing income		567,931			433,369			63,871				1,074,754			900,035			132,649
Tech-empowerment service income		830,124			473,053			69,719				1,454,974			1,025,853			151,192
Installment e-commerce platform service income		487,444			783,684			115,501				775,827			1,308,351			192,827
Total operating revenue		3,587,414			3,187,008			469,707				6,691,513			6,496,146			957,413
Operating cost
Cost of sales		(425,900	)		(484,419	)		(71,395	)			(687,932	)		(833,118	)		(122,786	)
Funding cost		(59,940	)		(24,504	)		(3,611	)			(142,944	)		(80,146	)		(11,812	)
Processing and servicing cost		(605,652	)		(546,287	)		(80,513	)			(1,156,793	)		(1,180,137	)		(173,931	)
Provision for financing receivables		(256,857	)		(410,100	)		(60,441	)			(439,006	)		(750,760	)		(110,648	)
Provision for contract assets and receivables		(164,224	)		(173,689	)		(25,599	)			(293,909	)		(310,198	)		(45,718	)
Provision for contingent guarantee liabilities		(802,157	)		(1,052,289	)		(155,088	)			(1,479,337	)		(2,011,441	)		(296,450	)
Total operating cost		(2,314,730	)		(2,691,288	)		(396,647	)			(4,199,921	)		(5,165,800	)		(761,345	)
Gross profit		1,272,684			495,720			73,060				2,491,592			1,330,346			196,068
Operating expenses:
Sales and marketing expenses		(567,025	)		(346,996	)		(51,141	)			(1,060,153	)		(858,952	)		(126,594	)
Research and development expenses		(157,680	)		(146,681	)		(21,618	)			(313,306	)		(294,973	)		(43,474	)
General and administrative expenses		(96,010	)		(107,320	)		(15,817	)			(196,763	)		(204,825	)		(30,187	)
Total operating expenses		(820,715	)		(600,997	)		(88,576	)			(1,570,222	)		(1,358,750	)		(200,255	)
Change in fair value of financial guarantee derivatives and loans at fair value		184,089			238,381			35,133				258,728			399,600			58,894
Interest expense, net		(4,621	)		(6,395	)		(943	)			(9,323	)		(11,703	)		(1,725	)
Investment loss		(5,126	)		(4,138	)		(610	)			(16,825	)		(7,646	)		(1,127	)
Others, net		4,997			32,211			4,747				8,829			72,341			10,662
Income before income tax expense		631,308			154,782			22,811				1,162,779			424,188			62,517
Income tax expense		(119,907	)		(53,467	)		(7,880	)			(221,054	)		(121,433	)		(17,897	)
Net income		511,401			101,315			14,931				941,725			302,755			44,620
Net income attributable to ordinary shareholders of the Company		511,401			101,315			14,931				941,725			302,755			44,620
Net income per ordinary share attributable to ordinary shareholders of the Company
Basic		1.50			0.31			0.05				2.78			0.91			0.13
Diluted		1.43			0.30			0.04				2.62			0.90			0.13
Net income per ADS attributable to ordinary shareholders of the Company
Basic		3.00			0.61			0.09				5.55			1.83			0.27
Diluted		2.85			0.61			0.09				5.25			1.81			0.27
Weighted average ordinary shares outstanding
Basic		340,489,447			330,298,998			330,298,998				339,288,258			330,946,369			330,946,369
Diluted		358,475,575			333,417,483			333,417,483				359,067,911			335,031,820			335,031,820

LexinFintech Holdings Ltd. Unaudited Condensed Consolidated Statements of Comprehensive Income
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
(In thousands)	2025			2026							2025			2026
	RMB			RMB			US$				RMB			RMB			US$
Net income		511,401			101,315			14,931				941,725			302,755			44,620
Other comprehensive income
Foreign currency translation adjustment, net of nil tax		7,695			(2,707	)		(399	)			5,436			255			38
Total comprehensive income		519,096			98,608			14,532				947,161			303,010			44,658
Total comprehensive income attributable to ordinary shareholders of the Company		519,096			98,608			14,532				947,161			303,010			44,658

LexinFintech Holdings Ltd. Unaudited Reconciliations of GAAP and Non-GAAP Results
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
(In thousands, except for share and per share data)	2025			2026							2025			2026
	RMB			RMB			US$				RMB			RMB			US$
Reconciliation of Adjusted net income attributable to ordinary shareholders of the Company to Net income attributable to ordinary shareholders of the Company
Net income attributable to ordinary shareholders of the Company		511,401			101,315			14,931				941,725			302,755			44,620
Add: Share-based compensation expenses		24,183			22,022			3,246				53,724			45,128			6,651
Investment loss		5,126			4,138			610				16,825			7,646			1,127
Adjusted net income attributable to ordinary shareholders of the Company		540,710			127,475			18,787				1,012,274			355,529			52,398
Adjusted net income per ordinary share attributable to ordinary shareholders of the Company
Basic		1.59			0.39			0.06				2.98			1.07			0.16
Diluted		1.51			0.38			0.06				2.82			1.06			0.16
Adjusted net income per ADS attributable to ordinary shareholders of the Company
Basic		3.18			0.77			0.11				5.97			2.15			0.32
Diluted		3.02			0.76			0.11				5.64			2.12			0.31
Weighted average shares used in calculating net income per ordinary share for non-GAAP EPS
Basic		340,489,447			330,298,998			330,298,998				339,288,258			330,946,369			330,946,369
Diluted		358,475,575			333,417,483			333,417,483				359,067,911			335,031,820			335,031,820
Reconciliations of Non-GAAP EBIT to Net income
Net income		511,401			101,315			14,931				941,725			302,755			44,620
Add: Income tax expense		119,907			53,467			7,880				221,054			121,433			17,897
Share-based compensation expenses		24,183			22,022			3,246				53,724			45,128			6,651
Interest expense, net		4,621			6,395			943				9,323			11,703			1,725
Investment loss		5,126			4,138			610				16,825			7,646			1,127
Non-GAAP EBIT		665,238			187,337			27,610				1,242,651			488,665			72,020

Additional Credit Information

Vintage Charge Off Curve

¹

Dpd30+/GMV by Performance Windows

¹

First Payment Default 30+

¹

1.     Loans facilitated under ICP and E-commerce business are excluded from the charts.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (“PFS”) versus TAGRISSO^® alone in both the high MET and intention-to-treat (“ITT”) patient populations.

In both patient populations, the combination also demonstrated a very encouraging clinical benefit in overall survival (“OS”), a secondary endpoint of the trial. The trial will continue to follow-up on these results. These data will be presented at a forthcoming medical meeting.

Professor Yi-Long Wu of the Guangdong Provincial People’s Hospital, and the leading Principal Investigator of the SANOVO trial, said: “Co-occurring MET overexpression in treatment-naïve EGFR-mutated NSCLC often compromises the long-term durability of EGFR-TKI monotherapy. The positive findings from SANOVO demonstrate that addressing both pathways upfront with an all-oral, biomarker-directed regimen offers a powerful new approach for these patients whose tumors have MET overexpression. By combining ORPATHYS^® with TAGRISSO^®, we have observed a clear clinical benefit that could reshape primary treatment strategy for this distinct patient population.”

Dr Weiguo Su, Chief Executive Officer

^*

and Chief Scientific Officer of HUTCHMED, said: “We are thrilled by the positive results from SANOVO, which validate our strategy of addressing MET-driven disease across multiple stages of lung cancer. Building on the strong foundations of our Phase III SAFFRON global study and SACHI study in China in pre-treated patients, SANOVO data further validate the therapeutic strength and versatility of the ORPATHYS^® and TAGRISSO^® combination in first-line patients. We are deeply grateful to all patients and investigators who participated in the trial, and we look forward to sharing the data with regulatory authorities to bring this innovative all-oral combination to the first-line setting in China.”

Dr Jing He, Head of R&D China, AstraZeneca, said: “These positive data underscore the pivotal role of ORPATHYS^® in intercepting MET-driven resistance early in the treatment journey. By combining the targeted precision of ORPATHYS^® with backbone TAGRISSO^®, SANOVO demonstrates a meaningful clinical advancement for treatment-naïve patients with MET overexpression and EGFR mutation. Together with HUTCHMED, we are excited to advance ORPATHYS^® in China as a transformative, biomarker-directed addition to frontline lung cancer care.”

The safety profile for ORPATHYS^® plus TAGRISSO^® was consistent with the known profiles of each medicine, and there were no new safety findings.

ORPATHYS^® plus TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR-mutated (“EGFRm”) NSCLC with MET amplification after disease progression on EGFR-tyrosine kinase inhibitor (“TKI”) therapy based on the SACHI Phase III trial. The combination also reported positive high-level results in the SAFFRON global Phase III trial in EGFRm NSCLC with MET overexpression or amplification after disease progression on TAGRISSO^® in August 2026, demonstrating a statistically significant and clinically meaningful improvement in both PFS and overall survival (“OS”).

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of death by cancer globally, accounting for almost one in four (23%) cancer deaths.¹ Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.² Approximately 75% of NSCLC patients are diagnosed with advanced disease.³ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^4,5,6

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁷ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^7,8

About SANOVO

SANOVO is a blinded, randomized, controlled Phase III study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China. The study evaluates the efficacy and safety of ORPATHYS^® in combination with TAGRISSO^® comparing to TAGRISSO^® alone, a standard-of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic NSCLC harboring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO^® 80 mg once daily plus either ORPATHYS^® or placebo at 300/200 mg twice daily (dosed based on body weight).

The primary endpoint of the study is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety. Additional details may be found at clinicaltrials.gov, using identifier NCT05009836.

About ORPATHYS

^®


ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with platinum-based chemotherapy, reported positive high-level results demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO

^®


TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS

^®

, the further clinical development for ORPATHYS

^®

, its expectations as to whether any studies on ORPATHYS

^®

would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS

^®

, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS

^®

for a targeted indication; the sufficiency of funding; and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS

^®

. In addition, as certain studies rely on the use of other drug products such as TAGRISSO

^®

as combination therapeutics with ORPATHYS

^®

, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

Inside Information

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).

Medical Information

This announcement contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / [email protected]
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / [email protected]
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / [email protected]
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

^* currently on leave of absence.

REFERENCES

1	World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://​gco.iarc.who.int/​media/​globocan/​factsheets/​cancers/​15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed August 2026.
2	American Cancer Society. What Is Lung Cancer? Available at: https://​www.cancer.org/​cancer/​types/​lung-cancer/​about/​what-is.html. Accessed August 2026.
3	Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.
4	Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.
5	Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First- Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-2127.
6	Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66:79-89.
7	Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074).
8	Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.

Did you buy RXT securities between May 7, 2026 and July 8, 2026
?

Affected RXT Investor Summary

• Who: Rackspace Technology, Inc. (NASDAQ: RXT)
• What: Securities fraud class action lawsuit filed
• Class Period: May 7, 2026 through July 8, 2026
• Deadline to Seek Lead Plaintiff Status: September 28, 2026
• Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s enterprise AI efforts.   
• Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options

RADNOR, Pa., Aug. 30, 2026 (GLOBE NEWSWIRE) — Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Rackspace Technology, Inc. (Rackspace) (NASDAQ: RXT) on behalf of those who purchased or acquired Rackspace securities between May 7, 2026 and July 8, 2026, inclusive. The lawsuit is filed in the United States District Court for the Southern District of New York and is captioned Morgan-Reed v. Rackspace Technology, Inc., No. 1:26-cv-06491 (S.D.N.Y.). Investors have until September 28, 2026, to file for lead plaintiff status.  

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:


If you purchased or acquired Rackspace securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/rxt-rackspace-technology-inc-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=rxt&mktm=PR

You can also contact attorney

Jonathan Naji, Esq.

by calling (484) 270-1453 or by email at

[email protected]

. There is no cost or obligation to speak with an attorney.

To view the Rackspace video on YouTube, click here:



https://youtu.be/SGYNCxPHZ2c?si=vzxUeEhLFRsDoqkR

RACKSPACE TECHNOLOGY, INC.


CLASS ACTION LAWSUIT – COMPLAINT ALLEGATION SUMMARY:


The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Rackspace’s enterprise AI efforts would require the company to significantly re-prioritize its capacity and capital away from the profitable Private Cloud segment; (2) Rackspace’s Public Cloud revenue was declining as customers contracted directly with hyperscale cloud platforms; (3) as a result, Rackspace was likely to significantly reduce a material portion of its Public Cloud infrastructure resale business; (4) consequently, Rackspace’s fiscal year 2026 revenue would be significantly impacted; and (5) as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why did Rackspace’s Stock Drop?

On July 9, 2026, before the market opened, Rackspace published its second quarter 2026 financial results and disclosed “a strategic and financial update on its transition to becoming the operator of the full enterprise AI stack.” Specifically, Rackspace revealed that its AI investments would require a significant re-prioritization of resources and, as a result, reduced its full year 2026 revenue guidance by $150 million. Rackspace also cut its full year 2026 Private Cloud revenue outlook by $25 million and explained that “[l]ower near-term margins reflect upfront growth investment and restructuring, ahead of AI revenue ramping.”

On this news, Rackspace’s stock price fell $2.21 per share, or 33.6%, to close at $4.37 per share on July 9, 2026.

WHAT RACKSPACE TECHNOLOGY, INC. INVESTORS CAN DO NOW:

1. File to be lead plaintiff by September 28, 2026.
2. Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.
3. Retain counsel of choice or take no action.

THE LEAD PLAINTIFF PROCESS FOR RACKSPACE TECHNOLOGY, INC. INVESTORS:


Rackspace investors may, no later than September 28, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP
encourages Rackspace investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.

CONTACT:

Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
        
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

– Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging,
 with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis

– Patients treated with acoramidis were observed to have an unprecedented 65 additional days alive and out of the hospital by Month 36 versus baseline placebo patients

– Acoramidis demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups, including p.Val142Ile and non-p.Val142Ile. These findings were simultaneously published in the

European Journal of Heart Failure

PALO ALTO, Calif., Aug. 30, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, presented new analyses from the Phase 3 ATTRibute-CM study of Attruby^® (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including the cardiac magnetic resonance imaging (CMR) substudy and the open-label extension (OLE) at the European Society of Cardiology (ESC) Congress 2026. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

“The clinical community is excited about the potential to restore heart health found in these data. For a long time, patients living with ATTR-CM could only hope for a stop to the otherwise relentless progression of disease. These new CMR data from ATTRibute-CM shows evidence of reversal in a meaningful proportion of individuals treated with acoramidis, with roughly half showing improved left ventricular systolic function in the completer analysis, more than 2x the proportion observed in the natural history from a NAC cohort or in ATTRibute-CM participants treated with placebo. These findings support acoramidis as a therapy capable of altering the trajectory of this otherwise progressive disease,” said Marianna Fontana, M.D. of University College London, UK. “For patients and clinicians navigating ATTR-CM, this is an exciting signal that the treatment paradigm is shifting toward a therapy that could actively restore heart health rather than only manage decline.”

The CMR substudy of ATTRibute-CM and its open-label extension provide the first evidence from serial CMR that a therapy can potentially reverse disease progression through Month 42. The findings presented by Awais Sheikh, MBChB of the National Amyloidosis Centre, London, UK were evaluated using two complementary analytical approaches, which found:

• In a completer analysis, clinically meaningful improvement from baseline in left ventricular (LV) systolic function was observed in 54% of acoramidis-treated patients versus 20% of placebo-treated patients at Month 30, and in 53% of continuous-acoramidis patients at Month 42
• For context, only 26% of completers in an independent natural history cohort demonstrated improved LV systolic function by Month 24 – approximately half the rate observed with acoramidis, suggesting that this magnitude of improvement falls outside the expected natural course of disease
• In a conservative analysis, long-term acoramidis treatment was associated with clinically meaningful improvement from baseline in LV systolic function in approximately one-third of patients over 30-42 months. Improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month 30 and in 30% of continuous-acoramidis patients at Month 42
• In addition, 46% of patients receiving continuous acoramidis demonstrated improvement from baseline in LV mass index at Month 42, providing evidence of favorable structural remodeling
• These results provided sufficient evidence for BridgeBio to recently dose its first participant in ASCEND-ATTR, a Phase 3b/4 study designed to determine if acoramidis is associated with sustained improvement in myocardial structural disease progression, function and amyloid burden

In a post-hoc analysis of ATTRibute-CM presented by Richard Wright, M.D. of the Pacific Heart Institute, U.S., acoramidis preserved significantly more time alive outside the hospital for patients with ATTR-CM. The analysis evaluated days lost to death and/or cardiovascular-related hospitalization (DLDCVH), a patient-centered measure that integrates all-cause mortality, cardiovascular-related hospitalizations, and length of stay into a single assessment of disease burden. Key findings included:

• In participants with ATTR-CM, acoramidis reduced the estimated mean percentage of DLDCVH to 7.5% versus 11.7% with placebo through Month 30
• Acoramidis preserved more than one month of additional time alive and out of the hospital (38 days) over 30 months with the benefit nearly doubling to 65 days (observed) over three years, and nearly tripling to up to 94 days (modelled estimates) over three years, reflecting progressive divergence in outcomes over time

The p.Val142Ile genetic variant is the most common ATTR-CM genetic variant globally, disproportionately affecting individuals of Western African ancestry, with a carrier frequency of 3-4% in the U.S. Black population. Findings in the ATTRibute-CM OLE presented by Kevin Alexander, M.D. of Stanford University School of Medicine, U.S. showed continued benefit of acoramidis in 56 variant ATTR-CM (ATTRv-CM) patients, including 35 p.Val142Ile and 21 non-p.Val142Ile patients through Month 54, demonstrating:

• All-cause mortality (ACM) and cardiovascular mortality (CVM) were markedly lower in the continuous acoramidis arm versus placebo-to-acoramidis across both p.Val142Ile and non-p.Val142Ile variant subgroups
• Through Month 54, ACM was 30.4% with continuous acoramidis versus 66.7% with placebo-to-acoramidis in the p.Val142Ile subgroup, and 24.3% with continuous acoramidis versus 57.9% with placebo-to-acoramidis across the overall ATTRv-CM population, a consistent, more than two-fold difference in mortality favoring continuous treatment
• The ACM and CVM rates at Month 54 were notably high (~65%) in the p.Val142Ile group who were randomized to placebo in ATTRibute-CM, underscoring the substantial unmet medical need in this high-risk subgroup
• Continuous acoramidis achieved sustained increases in serum TTR (sTTR) and persistent attenuation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) rise through Month 54 in both participants with p.Val142Ile or non-p.Val142Ile variants
• These Month 54 findings extend the survival benefit and favorable biomarker trends previously reported at Month 30, demonstrating the long-term durability of efficacy and safety of acoramidis in ATTRv-CM, including in the p.Val142Ile subgroup
• Acoramidis remained well tolerated through Month 54, with no new safety signals observed in the OLE

In addition to the one oral presentation and two moderated posters highlighted, two additional moderated posters on acoramidis were shared at the ESC Congress 2026, including:

• Acoramidis Improves Health-Related Quality of Life in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: An EQ-5D-5L Subgroup Analysis from ATTRibute-CM, presented by Emer Joyce, M.D., Ph.D. of The Mater Misericordiae University Hospital, IE
  • Treatment with acoramidis resulted in significant and clinically meaningful benefits in health-related quality of life (HRQoL) in both wild-type ATTR-CM (ATTRwt-CM) and ATTRv-CM. Greater impact on HRQoL versus placebo was observed in participants with ATTRv-CM
• Improvement of Health Status with Acoramidis in Patients with Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: KCCQ Domains Analysis from the ATTRibute-CM Study, presented by Nitasha Sarswat, M.D. of University of Chicago Medical Center, U.S.
  • In ATTRibute-CM, acoramidis attenuated the decline in heart failure-related health status versus placebo in participants with ATTRwt-CM and ATTRv-CM, with consistent benefits observed across Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) and individual domain scores. A numerical improvement was observed across almost all KCCQ domains in acoramidis-treated participants with ATTRwt-CM and ATTRv-CM relative to placebo

As part of BridgeBio’s partnership with Yale’s Cardiovascular Data Science (CarDS) Lab to advance AI networks for earlier detection of ATTR-CM, three posters were presented at the ESC Congress 2026. Findings from the partnership included:

• A Novel AI-Derived Digital Biomarker for Monitoring Disease Progression in ATTR-CM: First-In-Trial Use of a Computer Vision AI-ECG Algorithm within a Phase 3 Pivotal Randomized Controlled Trial, presented by Rohan Khera, M.D. of Yale School of Medicine, U.S.
  • This showed the first deployment of a computer vision AI-ECG algorithm, operating directly on ECG data, as a digital biomarker in a RCT (ATTRibute-CM). An image-based AI-ECG algorithm demonstrated discrimination across clinical subgroups at baseline and detected differential longitudinal changes between acoramidis and placebo over 30 months. These findings support the potential role of AI-ECG derived prediction scores as a scalable digital biomarker in clinical trials and potential routine cardiovascular care
• A Fully Decentralized, Patient-Led Digital Registry for ATTR-CM Integrating Multisystem EHR and Wearable Data: The DISCOVER-ATTR Study, presented by Aline Pedroso, Ph.D. of Yale School of Medicine
  • A fully decentralized, patient-led digital registry can successfully aggregate longitudinal multisystem electronic health records (EHR) data and wearable physiologic signals in ATTR-CM. Early results show substantial data yield and feasibility of longitudinal mapping of care trajectories and multimodal risk prediction, providing a blueprint for next-generation registries in rare cardiovascular diseases
• Nationwide U.S. Federated Deployment of Artificial Intelligence for Multimodal Screening of ATTR Cardiomyopathy: First Multicenter Analysis from the TRACE-AI Network, presented by Bruno Batinica, MBChB of Yale School of Medicine
  • In this largest-ever deployment of AI-electrocardiogram and AI-Echo models for opportunistic retrospective screening of individuals at risk of ATTR-CM, we demonstrate a large burden of probable undiagnosed ATTR-CM with prognostic implications. Leveraging this framework for screening holds promise for enabling broad, timely identification of patients to maximize the overall benefit of new therapies

Acoramidis is approved as Attruby^® by the U.S. FDA and is approved as BEYONTTRA^® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Additional data on the benefit of Attruby for individuals with ATTR-CM is planned for future medical meetings, including Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, taking place in Phoenix, Arizona on October 9-12, 2026.

About Attruby^® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

BridgeBio Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data presented regarding acoramidis, including the potential clinical and therapeutic implications of observed changes in cardiac structure and function and the potential for acoramidis to alter the trajectory of ATTR-CM and restore heart health; the potential utility of AI-based tools and digital biomarkers for the detection, monitoring and screening of ATTR-CM in clinical trials and clinical practice; and BridgeBio’s plans to present additional data regarding Attruby at future medical meetings. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data, the design and success of ongoing and planned clinical trials, the risk that results from post hoc analyses, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects, that observed improvements in cardiac structure, function or other measures may not be replicated in additional analyses or studies or translate into improved long-term clinical outcomes, that the potential utility of AI-based tools and digital biomarkers may not be demonstrated in further studies or translate into routine clinical use, that plans to present additional data may change, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

About BridgeBio

BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:

Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220

BridgeBio Investor Contact:

Kristen Kelleher, Director, Investor Relations
[email protected]